PERTH, Australia--(BUSINESS WIRE)--AION Diagnostics Inc is pleased to announce the completion of its successful spin-out from parent company pSivida Ltd. The successful spin-out was completed in conjunction with AION’s corporate advisor, New York based buyout specialist Global Emerging Markets (GEM). Following the spin-out AION’s executive management team retain a 39% shareholding in the Company, GEM a major shareholder at 27% and following a private placement of new shares, outside investors represent the remaining 34% interest. Following the spin-out AION now has 13.14 million shares on issue.
